No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group.

Leukemia & Lymphoma
Thoralf LangeDietger Niederwieser

Abstract

The combination of Imatinib (IM) and hydroxyurea (HU) was explored for the treatment of chronic myelogenous leukemia (CML). After in vitro testing and a phase I study (n = 20), 59 patients were randomized in the IM/HU and 29 in the IM arm. According to protocol, 49 propensity-score matched IM patients were included from the CML-IV study. Additive specific inhibition of CML cells by IM/HU was detected in vitro. HU 500 mg qd in combination with IM 400 mg qd proved feasible in the phase I study. Overall, no significant difference with respect to major molecular response (MMR) at 18 months (IM/HU and IM 66%; primary endpoint) was observed. Significant differences were noted for MMR at 6 months (p = 0.04) and for cumulative incidences of adverse events (p = 0.03) in favor of IM monotherapy (secondary endpoints). IM/HU combination was more potent in selectively inhibiting CML cells in vitro, but not superior to IM in vivo. (NCT02480608).

Associated Clinical Trials

References

May 1, 1990·American Journal of Hematology·R HerrW A Robinson
Sep 12, 2001·Bone Marrow Transplantation·M DeiningerUNKNOWN East German Study Group Haematology/Oncology (OSHO)
Oct 13, 2006·Statistics in Medicine·H PutterR B Geskus
Mar 23, 2013·British Journal of Pharmacology·A SinclairT L Holyoake
Dec 10, 2016·Blood·Delphine ReaUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques
Jan 18, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel EtienneFrançois-Xavier Mahon
Mar 9, 2017·The New England Journal of Medicine·Andreas HochhausUNKNOWN IRIS Investigators
Apr 4, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Leonardo CampiottiAlessandro Squizzato
Apr 3, 2020·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.